Selected demographic and clinical characteristics for all Angiotensin-Receptor-Blockers displayed by country
| Characteristics | USA (%) | Canada (%) | Denmark (%) | UK (%) |
| Number of ARB users | 10 836 991 | 1 775 080 | 1 153 841 | 3 270 823 |
| Number of episodes* | 22 406 719 | 798 231 | 492 229 | 578 652 |
| Individual ARB episodes | ||||
| Azilsartan | 0.6 | – | – | 0.005 |
| Candesartan | 0.9 | 27.5 | 4.8 | 34.2 |
| Eprosartan | 0.006 | – | – | 0.4 |
| Irbesartan | 5.2 | 18.3 | 0.6 | 10.2 |
| Losartan | 67.9 | 11.4 | 93.5 | 48.3 |
| Olmesartan | 8.6 | 12.2 | – | 2.3 |
| Telmisartan | 2.2 | 21.1 | 0.4 | 1.9 |
| Valsartan | 18.4 | 16.3 | 1.0 | 3.1 |
| Age | ||||
| 18–44 years | 5.5 | 3.5 | 5.6 | 3.6 |
| 45–64 years | 25.8 | 17.6 | 39.1 | 32.8 |
| ≥65 years | 68.7 | 78.9 | 55.3 | 63.7 |
| Gender | ||||
| Female | 55.9 | 54.5 | 51.4 | 53.5 |
| Male | 44.1 | 45.5 | 48.6 | 46.5 |
| Race | ||||
| American Indian or Alaska Native | 0.3 | NR | NR | NR |
| Asian | 2.4 | NR | NR | NR |
| Black or African American | 10.0 | NR | NR | NR |
| Native Hawaiian or Other Pacific Islander | 0.2 | NR | NR | NR |
| White | 56.7 | NR | NR | NR |
| Unknown | 30.3 | NR | NR | NR |
| Ethnicity | NR | NR | NR | |
| Hispanic origin | 2.3 | NR | NR | NR |
| Clinical history† | ||||
| Angina | 17.4 | 3.4 | NR | 0.8 |
| Atrial fibrillation | 10.9 | 5.6 | NR | 2.4 |
| Diabetes | 36.6 | 25.0 | NR | 13.2 |
| Heart failure | 12.3 | 4.1 | NR | 1.6 |
| Hyperlipidaemia | 57.2 | 4.7 | NR | 0.9 |
| Hypertension | 86.1 | 46.1 | NR | 25.3 |
| Myocardial infarction | 2.2 | 1.1 | NR | 0.7 |
| Renal disorders | 20.7 | 5.4 | NR | 2.8 |
| Stroke | 4.7 | 1.8 | NR | 1.6 |
*An ARB episode occurs when ARB dispensings are bridged together ensuring continuous exposure to an ARB. The number of days of product supplied per dispensing or the number of days the product was prescribed by bridging together episodes less than 30 days apart and adding 30 days to the end of each episode.
†Clinical History collected 183 days before the index date.
NR, not reported.